Resmed's new aircurve™ 11 bilevel devices enable healthcare providers to make informed decisions about care, deliver personalized support, and drive positive therapy outcomes for patients with sleep apnea

Enhances availability of device therapy options, particularly for those who struggle with single pressure pap therapy part of air11 solutions, key features include care check-in, personal therapy assistant, among others to provide support to patients and insights to clinicians and providers when used with airview and myair app san diego, feb. 12, 2024 (globe newswire) -- resmed (nyse: rmd, asx: rmd) launched today its aircurve 11 series devices, the company's newest bilevel devices that use two levels of support, inspiratory positive airway pressure (ipap) and expiratory positive airway pressure (epap), combined with digital technology to make it easier for healthcare providers to treat sleep apnea and to help patients start and stay on therapy. aircurve 11 devices are built on resmed's market-leading airsense 11 platform and enhance the suite of offerings available for healthcare providers and clinicians when determining the best care for sleep apnea patients.
RMD Ratings Summary
RMD Quant Ranking